Skip to main content

Bruker Value Stock - Dividend - Research Selection

Bruker

ISIN: US1167941087 , WKN: 813534

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!

How our site works ...

✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month 
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry systems; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies. The company also provides X-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and X-ray metrology, and defect-detection equipment for semiconductor process control, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments and spark optical emission spectroscopy systems. In addition, it offers superconducting and non-superconducting materials and devices. The company serves pharmaceutical, biotechnology and diagnostics, chemical, food and beverage, clinical, polymer, nanotechnology, semiconductor, and industrial companies; nonprofit laboratories; contract research organizations, academic institutions, medical schools, nonprofit or for-profit forensics, agriculture, food and beverage safety, environmental and clinical microbiology laboratories, hospitals, and government departments and agencies; and raw material manufacturers, and other businesses involved in materials analysis. It markets its products through direct sales forces, distributors, independent sales representatives, and other representatives. Bruker Corporation was founded in 1991 and is headquartered in Billerica, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


3 Reasons BRKR is Risky and 1 Stock to Buy Instead

2026-10-12
Bruker has been on fire lately. In the past six months alone, the company’s stock price has rocketed 50.7%, reaching $58.84 per share. This run-up might have investors contemplating their next move.

Why Is Bruker (BRKR) Getting Attention For Its Human Plasma Proteome Atlas?

2026-10-09
Bruker (NasdaqGS:BRKR) and Charité have released a draft atlas of the human plasma proteome at proteoform resolution. The project maps more than 179,000 distinct plasma proteoforms, using Bruker's timsTOF mass spectrometry platform as a core technology. The partners have made the dataset available as a public preprint to support broader proteomics research and clinical discovery work. The new human plasma proteoform atlas is important, but investors should weigh it alongside other factors...

Bruker (BRKR), Why Is Its Latest Update Drawing Fresh Attention?

2026-10-08
Bruker (BRKR) just rolled out new timsUltra AIP and timsOmni workflows, extending its mass spectrometry platform into deeper protein sequencing, glycopeptide analysis, structural proteomics, and oligonucleotide characterization, which could matter for long term product relevance. Against this product news, Bruker’s 1-day share price return declined 1.29% and the 7-day share price return fell 7.77%. However, the year-to-date share price return of 24.13% and 1-year total shareholder return of...

Bruker Gains 66.3% in a Year: What's Driving the Rally?

2026-10-08
BRKR shares surge 66.3% in a year, fueled by strong demand in mass spectrometry and biopharma, despite restructuring challenges and currency headwinds.

Barclays Maintains Overweight on Bruker, Raises Price Target to $70

2026-10-07
Barclays analyst Luke Sergott maintains Bruker (NASDAQ:BRKR) with a Overweight and raises the price target from $58 to $70.

3 Cash-Producing Stocks We Steer Clear Of

2026-10-07
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

Untargeted timsTOF Mass Spectrometry Enables Discovery and Mapping of Draft Atlas of the Human Plasma Proteome at Proteoform Resolution

2026-10-06
BERLIN, October 06, 2026--Bruker Corporation (Nasdaq: BRKR) announced a seminal bioRxiv preprint, describing a draft atlas of the human plasma proteome at isoform, or proteoform, resolution. The study was conducted by principal investigator Markus Ralser at Charité – Universitätsmedizin Berlin and collaborators. The preprint "A draft atlas of the human plasma proteome at isoform resolution" was posted on September 28, 2026 at https://doi.org/10.64898/2026.09.26.754256.

Are Options Traders Betting on a Big Move in Bruker Stock?

2026-10-05
Investors need to pay close attention to BRKR stock based on the movements in the options market lately.

1 Surging Stock to Target This Week and 2 We Question

2026-10-05
Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions.

QIAGEN Expands US QIAstat-Dx Portfolio With New FDA-Cleared Panel

2026-10-02
QGEN expands its U.S. QIAstat-Dx portfolio with an FDA-cleared panel that detects gram-negative bacteria and resistance markers in about one hour.